New guidelines from the NCCN for polycythemia vera.
作者信息
Mesa Ruben A
机构信息
University of Texas Health Science Center, San Antonio, Texas.
出版信息
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850.
Abstract
摘要
相似文献
1
New guidelines from the NCCN for polycythemia vera.
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850.
2
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
J Natl Compr Canc Netw. 2018 Dec;16(12):1539-1545. doi: 10.6004/jnccn.2018.7073.
3
From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?
Leukemia. 2020 Nov;34(11):2837-2839. doi: 10.1038/s41375-020-0984-9. Epub 2020 Jul 16.
4
[Polycythemia vera: the disadvantages of overproduction].
MMW Fortschr Med. 2015 Apr 30;157(8):18-20. doi: 10.1007/s15006-015-3012-7.
5
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Haematologica. 2017 Jan;102(1):103-109. doi: 10.3324/haematol.2016.152769. Epub 2016 Sep 29.
6
Treatment target in polycythemia vera.
N Engl J Med. 2013 Apr 18;368(16):1555-6. doi: 10.1056/NEJMc1301262.
7
Treatment target in polycythemia vera.
N Engl J Med. 2013 Apr 18;368(16):1554-5. doi: 10.1056/NEJMc1301262.
8
Treatment target in polycythemia vera.
N Engl J Med. 2013 Apr 18;368(16):1555. doi: 10.1056/NEJMc1301262.
9
Treatment target in polycythemia vera.
N Engl J Med. 2013 Apr 18;368(16):1556-7. doi: 10.1056/NEJMc1301262.
10
Treatment target in polycythemia vera.
N Engl J Med. 2013 Apr 18;368(16):1556. doi: 10.1056/NEJMc1301262.
引用本文的文献
1
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
Ann Hematol. 2025 Jul 18. doi: 10.1007/s00277-025-06466-z.
2
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study.
Ther Adv Hematol. 2025 Jul 4;16:20406207251342199. doi: 10.1177/20406207251342199. eCollection 2025.
3
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.
Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925.
4
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Life (Basel). 2021 Oct 30;11(11):1158. doi: 10.3390/life11111158.
5
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Blood Cancer J. 2021 Mar 6;11(3):53. doi: 10.1038/s41408-021-00445-z.
6
Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.
Turk J Haematol. 2020 Aug 28;37(3):177-185. doi: 10.4274/tjh.galenos.2020.2019.0431. Epub 2020 Feb 20.
7
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11.
本文引用的文献
1
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.
2
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.
3
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
Zotero 插件